Dr. Hammers on Next Steps with Immunotherapy in RCC – OncLive
OncLive |
Dr. Hammers on Next Steps with Immunotherapy in RCC
OncLive Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC). Data are still needed to determine the response of nivolumab … |
